{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T01:53:20Z","timestamp":1780106000815,"version":"3.54.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T00:00:00Z","timestamp":1773100800000},"content-version":"vor","delay-in-days":32,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"MNESYS","award":["PE0000006"],"award-info":[{"award-number":["PE0000006"]}]},{"name":"European Union-Next Generation EU","award":["P20225W97A"],"award-info":[{"award-number":["P20225W97A"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-07781-3","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T08:09:39Z","timestamp":1770365379000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Formyl peptide receptor 2 activation by MR-39 inhibits glioblastoma cell proliferation and invasiveness through suppression of multiple oncogenic pathways"],"prefix":"10.1186","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3022-1205","authenticated-orcid":false,"given":"Maria Grazia","family":"Ferraro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Bocchetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Affinito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ercolano","family":"Giuseppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kardelen","family":"Dalim Filiz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luisa","family":"Speranza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enza","family":"Lacivita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcello","family":"Leopoldo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marianna","family":"Crispino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Ceccarelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Perrone-Capano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Concetta","family":"Miniaci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Caraglia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0618-5504","authenticated-orcid":false,"given":"Floriana","family":"Volpicelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"7781_CR1","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1001\/jama.2023.0023","volume":"329","author":"LR Schaff","year":"2023","unstructured":"Schaff LR, Mellinghoff IK. Glioblastoma and other primary brain malignancies in adults: A review. JAMA. 2023;329:574. https:\/\/doi.org\/10.1001\/jama.2023.0023.","journal-title":"JAMA"},{"key":"7781_CR2","doi-asserted-by":"publisher","first-page":"111801","DOI":"10.1016\/j.mad.2023.111801","volume":"211","author":"A Colopi","year":"2023","unstructured":"Colopi A, Fuda S, Santi S, Onorato A, Cesarini V, Salvati M, et al. Impact of age and gender on glioblastoma onset, progression, and management. Mech Ageing Dev. 2023;211:111801. https:\/\/doi.org\/10.1016\/j.mad.2023.111801.","journal-title":"Mech Ageing Dev"},{"key":"7781_CR3","doi-asserted-by":"publisher","first-page":"95","DOI":"10.3978\/j.issn.2305-5839.2015.03.57","volume":"3","author":"K Vigneswaran","year":"2015","unstructured":"Vigneswaran K, Neill S, Hadjipanayis CG. Beyond the world health organization grading of infiltrating gliomas: advances in the molecular genetics of glioma classification. Ann Transl Med. 2015;3:95. https:\/\/doi.org\/10.3978\/j.issn.2305-5839.2015.03.57.","journal-title":"Ann Transl Med"},{"key":"7781_CR4","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1056\/NEJMoa043330","volume":"352","author":"R Stupp","year":"2005","unstructured":"Stupp R, Van Den Mason WP, Weller M, Fisher B, Taphoorn MJB, et al. Radiotherapy plus concomitant and adjuvant Temozolomide for glioblastoma. N Engl J Med. 2005;352:987\u201396. https:\/\/doi.org\/10.1056\/NEJMoa043330.","journal-title":"N Engl J Med"},{"key":"7781_CR5","doi-asserted-by":"publisher","first-page":"1534","DOI":"10.1038\/s43018-022-00475-x","volume":"3","author":"L Wang","year":"2022","unstructured":"Wang L, Jung J, Babikir H, Shamardani K, Jain S, Feng X, et al. A single-cell atlas of glioblastoma evolution under therapy reveals cell-intrinsic and cell-extrinsic therapeutic targets. Nat Cancer. 2022;3:1534\u201352. https:\/\/doi.org\/10.1038\/s43018-022-00475-x.","journal-title":"Nat Cancer"},{"key":"7781_CR6","doi-asserted-by":"publisher","first-page":"657","DOI":"10.3892\/or.2016.5309","volume":"37","author":"G Wang","year":"2017","unstructured":"Wang G, Wang J-J, Fu X-L, Guang R, To S-ST. Advances in the targeting of HIF-1\u03b1 and future therapeutic strategies for glioblastoma multiforme. Oncol Rep. 2017;37:657\u201370. https:\/\/doi.org\/10.3892\/or.2016.5309.","journal-title":"Oncol Rep"},{"key":"7781_CR7","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.3390\/cells8111397","volume":"8","author":"S Nicolas","year":"2019","unstructured":"Nicolas S, Abdellatef S, Haddad MA, Fakhoury I, El-Sibai M, Hypoxia EGF, Stimulation Regulate. VEGF expression in human glioblastoma multiforme (GBM) cells by differential regulation of the PI3K\/Rho-GTPase and MAPK pathways. Cells. 2019;8:1397. https:\/\/doi.org\/10.3390\/cells8111397.","journal-title":"Cells"},{"key":"7781_CR8","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.62347\/RNUE7193","volume":"15","author":"X Liu","year":"2025","unstructured":"Liu X. Treatment mechanism and research progress of bevacizumab for glioblastoma. Am J Cancer Res. 2025;15:1874\u2013901. https:\/\/doi.org\/10.62347\/RNUE7193.","journal-title":"Am J Cancer Res"},{"key":"7781_CR9","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1146\/annurev.immunol.25.022106.141647","volume":"25","author":"CN Serhan","year":"2007","unstructured":"Serhan CN. Resolution phase of inflammation: novel endogenous Anti-Inflammatory and proresolving lipid mediators and pathways. Annu Rev Immunol. 2007;25:101\u201337. https:\/\/doi.org\/10.1146\/annurev.immunol.25.022106.141647.","journal-title":"Annu Rev Immunol"},{"key":"7781_CR10","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1007\/s004410051042","volume":"292","author":"EL Becker","year":"1998","unstructured":"Becker EL, Forouhar FA, Grunnet ML, Boulay F, Tardif M, Bormann B-J, et al. Broad immunocytochemical localization of the formylpeptide receptor in human organs, tissues, and cells. Cell Tissue Res. 1998;292:129\u201335. https:\/\/doi.org\/10.1007\/s004410051042.","journal-title":"Cell Tissue Res"},{"key":"7781_CR11","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/S1359-6101(01)00003-X","volume":"12","author":"Y Le","year":"2001","unstructured":"Le Y, Oppenheim J, Wang J. Pleiotropic roles of formyl peptide receptors. Cytokine Growth Factor Rev. 2001;12:91\u2013105. https:\/\/doi.org\/10.1016\/S1359-6101(01)00003-X.","journal-title":"Cytokine Growth Factor Rev"},{"key":"7781_CR12","doi-asserted-by":"publisher","first-page":"501","DOI":"10.1016\/j.cytogfr.2006.09.009","volume":"17","author":"I Migeotte","year":"2006","unstructured":"Migeotte I, Communi D, Parmentier M. Formyl peptide receptors: A promiscuous subfamily of G protein-coupled receptors controlling immune responses. Cytokine Growth Factor Rev. 2006;17:501\u201319. https:\/\/doi.org\/10.1016\/j.cytogfr.2006.09.009.","journal-title":"Cytokine Growth Factor Rev"},{"key":"7781_CR13","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1124\/mol.64.4.841","volume":"64","author":"Y-S Bae","year":"2003","unstructured":"Bae Y-S, Song JY, Kim Y, He R, Ye RD, Kwak J-Y, et al. Differential activation of formyl peptide receptor signaling by peptide ligands. Mol Pharmacol. 2003;64:841\u20137. https:\/\/doi.org\/10.1124\/mol.64.4.841.","journal-title":"Mol Pharmacol"},{"key":"7781_CR14","doi-asserted-by":"publisher","first-page":"229","DOI":"10.2174\/1570159X17666191019170244","volume":"18","author":"E Trojan","year":"2020","unstructured":"Trojan E, Bryniarska N, Le\u015bkiewicz M, Regulska M, Chamera K, Szuster-G\u0142uszczak M, et al. The contribution of formyl peptide receptor dysfunction to the course of neuroinflammation: A potential role in the brain pathology. CN. 2020;18:229\u201349. https:\/\/doi.org\/10.2174\/1570159X17666191019170244.","journal-title":"CN"},{"key":"7781_CR15","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.2174\/1389557520666200719014433","volume":"20","author":"M Mastromarino","year":"2021","unstructured":"Mastromarino M, Lacivita E, Colabufo NA, Leopoldo M. G-Protein coupled receptors involved in the resolution of inflammation: ligands and therapeutic perspectives. MRMC. 2021;20:2090\u2013103. https:\/\/doi.org\/10.2174\/1389557520666200719014433.","journal-title":"MRMC"},{"key":"7781_CR16","doi-asserted-by":"publisher","first-page":"3153","DOI":"10.1038\/s41598-017-03368-7","volume":"7","author":"X-L Hou","year":"2017","unstructured":"Hou X-L, Ji C-D, Tang J, Wang Y-X, Xiang D-F, Li H-Q, et al. FPR2 promotes invasion and metastasis of gastric cancer cells and predicts the prognosis of patients. Sci Rep. 2017;7:3153. https:\/\/doi.org\/10.1038\/s41598-017-03368-7.","journal-title":"Sci Rep"},{"key":"7781_CR17","doi-asserted-by":"publisher","first-page":"785","DOI":"10.4149\/neo_2018_181123N890","volume":"66","author":"J Lu","year":"2019","unstructured":"Lu J, Zhao J, Jia C, Zhou L, Cai Y, Ni J, et al. FPR2 enhances colorectal cancer progression by promoting EMT process. Neo. 2019;66:785\u201391. https:\/\/doi.org\/10.4149\/Neo_2018_181123N890.","journal-title":"Neo"},{"key":"7781_CR18","doi-asserted-by":"publisher","first-page":"4061","DOI":"10.3390\/cancers15164061","volume":"15","author":"JA Pe\u00f1a Agudelo","year":"2023","unstructured":"Pe\u00f1a Agudelo JA, Pidre ML, Garcia Fallit M, P\u00e9rez K\u00fcper M, Zuccato C, Nicola Candia AJ, et al. Mitochondrial peptide humanin facilitates chemoresistance in glioblastoma cells. Cancers (Basel). 2023;15:4061. https:\/\/doi.org\/10.3390\/cancers15164061.","journal-title":"Cancers (Basel)"},{"key":"7781_CR19","doi-asserted-by":"publisher","first-page":"7610","DOI":"10.3390\/molecules26247610","volume":"26","author":"D Aissaoui-Zid","year":"2021","unstructured":"Aissaoui-Zid D, Saada M-C, Moslah W, Potier-Cartereau M, Lemettre A, Othman H, et al. AaTs-1: A tetrapeptide from androctonus australis Scorpion Venom, inhibiting U87 glioblastoma cells proliferation by p53 and FPRL-1 Up-Regulations. Molecules. 2021;26:7610. https:\/\/doi.org\/10.3390\/molecules26247610.","journal-title":"Molecules"},{"key":"7781_CR20","doi-asserted-by":"publisher","first-page":"120207","DOI":"10.1016\/j.jns.2022.120207","volume":"436","author":"B Chanez","year":"2022","unstructured":"Chanez B, Appay R, Guille A, Lagarde A, Colin C, Adelaide J, et al. Genomic analysis of paired IDHwt glioblastomas reveals recurrent alterations of MPDZ at relapse after radiotherapy and chemotherapy. J Neurol Sci. 2022;436:120207. https:\/\/doi.org\/10.1016\/j.jns.2022.120207.","journal-title":"J Neurol Sci"},{"key":"7781_CR21","doi-asserted-by":"publisher","first-page":"1099","DOI":"10.1007\/s00011-024-01885-6","volume":"73","author":"GP Suchitha","year":"2024","unstructured":"Suchitha GP, Devasahayam Arokia Balaya R, Prasad TSK, Dagamajalu S. A signaling network map of Lipoxin (LXA4): an anti-inflammatory molecule. Inflamm Res. 2024;73:1099\u2013106. https:\/\/doi.org\/10.1007\/s00011-024-01885-6.","journal-title":"Inflamm Res"},{"key":"7781_CR22","doi-asserted-by":"publisher","first-page":"4719","DOI":"10.7150\/jca.32456","volume":"10","author":"H Liu","year":"2019","unstructured":"Liu H, Zeng J, Huang W, Xu Q, Ye D, Sun R, et al. Colorectal cancer is associated with a deficiency of Lipoxin A 4, an endogenous Anti-inflammatory mediator. J Cancer. 2019;10:4719\u201330. https:\/\/doi.org\/10.7150\/jca.32456.","journal-title":"J Cancer"},{"key":"7781_CR23","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s13046-017-0655-5","volume":"36","author":"L Zong","year":"2017","unstructured":"Zong L, Chen K, Jiang Z, Chen X, Sun L, Ma J, et al. Lipoxin A4 reverses mesenchymal phenotypes to attenuate invasion and metastasis via the Inhibition of autocrine TGF-\u03b21 signaling in pancreatic cancer. J Exp Clin Cancer Res. 2017;36:181. https:\/\/doi.org\/10.1186\/s13046-017-0655-5.","journal-title":"J Exp Clin Cancer Res"},{"key":"7781_CR24","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1100\/tsw.2010.113","volume":"10","author":"M Romano","year":"2010","unstructured":"Romano M, Lipoxin, Aspirin-Triggered Lipoxins. Sci World J. 2010;10:1048\u201364. https:\/\/doi.org\/10.1100\/tsw.2010.113.","journal-title":"Sci World J"},{"key":"7781_CR25","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/j.ejmech.2017.09.023","volume":"141","author":"ML Stama","year":"2017","unstructured":"Stama ML, \u015alusarczyk J, Lacivita E, Kirpotina LN, Schepetkin IA, Chamera K, et al. Novel Ureidopropanamide based N-formyl peptide receptor 2 (FPR2) agonists with potential application for central nervous system disorders characterized by neuroinflammation. Eur J Med Chem. 2017;141:703\u201320. https:\/\/doi.org\/10.1016\/j.ejmech.2017.09.023.","journal-title":"Eur J Med Chem"},{"key":"7781_CR26","doi-asserted-by":"publisher","first-page":"1524","DOI":"10.3390\/cells10061524","volume":"10","author":"E Trojan","year":"2021","unstructured":"Trojan E, Tylek K, Le\u015bkiewicz M, Laso\u0144 W, Brandenburg L-O, Leopoldo M, et al. The N-Formyl peptide receptor 2 (FPR2) agonist MR-39 exhibits Anti-Inflammatory activity in LPS-Stimulated organotypic hippocampal cultures. Cells. 2021;10:1524. https:\/\/doi.org\/10.3390\/cells10061524.","journal-title":"Cells"},{"key":"7781_CR27","doi-asserted-by":"publisher","first-page":"6203","DOI":"10.1007\/s12035-021-02543-2","volume":"58","author":"E Trojan","year":"2021","unstructured":"Trojan E, Tylek K, Schr\u00f6der N, Kahl I, Brandenburg L-O, Mastromarino M, et al. The N-Formyl peptide receptor 2 (FPR2) agonist MR-39 improves ex vivo and in vivo amyloid beta (1\u201342)-Induced neuroinflammation in mouse models of alzheimer\u2019s disease. Mol Neurobiol. 2021;58:6203\u201321. https:\/\/doi.org\/10.1007\/s12035-021-02543-2.","journal-title":"Mol Neurobiol"},{"key":"7781_CR28","doi-asserted-by":"publisher","first-page":"161","DOI":"10.3390\/ph15020161","volume":"15","author":"C Cristiano","year":"2022","unstructured":"Cristiano C, Volpicelli F, Crispino M, Lacivita E, Russo R, Leopoldo M, et al. Behavioral, AntiInflammatory, and neuroprotective effects of a novel FPR2 agonist in two mouse models of autism. Pharmaceuticals. 2022;15:161. https:\/\/doi.org\/10.3390\/ph15020161.","journal-title":"Pharmaceuticals"},{"key":"7781_CR29","doi-asserted-by":"publisher","unstructured":"Gentile MT, Ciniglia C, Reccia MG, Volpicelli F, Gatti M, Thellung S, et al. G Condorelli editor 2015 Ruta graveolens L. Induces death of glioblastoma cells and neural Progenitors, but not of Neurons, via ERK 1\/2 and AKT activation. PLoS ONE 10 e0118864 https:\/\/doi.org\/10.1371\/journal.pone.0118864.","DOI":"10.1371\/journal.pone.0118864"},{"key":"7781_CR30","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1038\/s41392-021-00658-5","volume":"6","author":"H Zhao","year":"2021","unstructured":"Zhao H, Wu L, Yan G, Chen Y, Zhou M, Wu Y, et al. Inflammation and tumor progression: signaling pathways and targeted intervention. Sig Transduct Target Ther. 2021;6:263. https:\/\/doi.org\/10.1038\/s41392-021-00658-5.","journal-title":"Sig Transduct Target Ther"},{"key":"7781_CR31","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1002\/(SICI)1097-4652(200003)182:3<311::AID-JCP1>3.0.CO;2-9","volume":"182","author":"T Scholzen","year":"2000","unstructured":"Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. J Cell Phys. 2000;182:311\u201322. https:\/\/doi.org\/10.1002\/(SICI)1097-4652(200003)182:3%253C311::AID-JCP1%253E3.0.CO;2-9.","journal-title":"J Cell Phys"},{"key":"7781_CR32","doi-asserted-by":"publisher","DOI":"10.3892\/ijo.2011.1165","author":"R Probstmeier","year":"2011","unstructured":"Probstmeier R. Pharmacological targeting of the constitutively activated MEK\/MAPK-dependent signaling pathway in glioma cells inhibits cell proliferation and migration. Int J Oncol [Internet]. 2011. https:\/\/doi.org\/10.3892\/ijo.2011.1165. [cited 2025 Aug 26].","journal-title":"Int J Oncol [Internet]"},{"key":"7781_CR33","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1016\/j.advenzreg.2006.01.004","volume":"46","author":"JA McCubrey","year":"2006","unstructured":"McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, et al. Roles of the RAF\/MEK\/ERK and PI3K\/PTEN\/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul. 2006;46:249\u201379. https:\/\/doi.org\/10.1016\/j.advenzreg.2006.01.004.","journal-title":"Adv Enzyme Regul"},{"key":"7781_CR34","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1615\/CritRevEukaryotGeneExpr.2015015601","volume":"25","author":"R Kalkan","year":"2015","unstructured":"Kalkan R. Hypoxia is the driving force behind GBM and could be a new tool in GBM treatment. Crit Rev Eukaryot Gene Expr. 2015;25:363\u20139. https:\/\/doi.org\/10.1615\/CritRevEukaryotGeneExpr.2015015601.","journal-title":"Crit Rev Eukaryot Gene Expr"},{"key":"7781_CR35","doi-asserted-by":"publisher","first-page":"1069","DOI":"10.1007\/s11033-024-09996-3","volume":"51","author":"S Hasan","year":"2024","unstructured":"Hasan S, Mahmud Z, Hossain M, Islam S. Harnessing the role of aberrant cell signaling pathways in glioblastoma multiforme: a prospect towards the targeted therapy. Mol Biol Rep. 2024;51:1069. https:\/\/doi.org\/10.1007\/s11033-024-09996-3.","journal-title":"Mol Biol Rep"},{"key":"7781_CR36","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1159\/000016308","volume":"9","author":"B Wagenknecht","year":"1999","unstructured":"Wagenknecht B, Hermisson M, Eitel K, Weller M. Proteasome inhibitors induce p53\/p21Independent apoptosis in human glioma cells. Cell Physiol Biochem. 1999;9:117\u201325. https:\/\/doi.org\/10.1159\/000016308.","journal-title":"Cell Physiol Biochem"},{"key":"7781_CR37","doi-asserted-by":"publisher","first-page":"579","DOI":"10.2174\/0115680096265849231031101449","volume":"24","author":"AHL N\u00f3brega","year":"2024","unstructured":"N\u00f3brega AHL, Pimentel RS, Prado AP, Garcia J, Frozza RL, Bernardi A. Neuroinflammation in glioblastoma: the role of the microenvironmentin tumour progression. CCDT. 2024;24:579\u201394. https:\/\/doi.org\/10.2174\/0115680096265849231031101449.","journal-title":"CCDT"},{"key":"7781_CR38","doi-asserted-by":"publisher","first-page":"7883","DOI":"10.3390\/ijms26167883","volume":"26","author":"V Ramar","year":"2025","unstructured":"Ramar V, Guo S, Wang G, Liu M. The pivotal role of NF-\u03baB in glioblastoma: mechanisms of activation and therapeutic implications. IJMS. 2025;26:7883. https:\/\/doi.org\/10.3390\/ijms26167883.","journal-title":"IJMS"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-07781-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07781-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-07781-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T12:35:30Z","timestamp":1773146130000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-07781-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["7781"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-07781-3","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"13 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"All authors have reviewed and approved the manuscript for submission to the Journal of Translational Medicine.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no potential conflicts of interest related to this work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"342"}}